---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-218018"
form_type: "8-K"
ticker: "SLDB"
cik: "0001707502"
company_name: "Solid Biosciences Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:56:11.429266+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Solid Biosciences reports Q2 net loss $25.1M; cash runway into Q2 2024; SGT-003 IND on track

## Summary
- Net loss $25.1M in Q2 2022 vs $18.7M in Q2 2021; collaboration revenue $6.2M (up from $3.6M).
- Cash and investments $162.9M as of June 30, 2022; estimated runway into Q2 2024.
- Transition to transient transfection manufacturing for SGT-001; expects to continue dosing patients in 2023.
- Next-gen candidate SGT-003 on track for mid-2023 IND submission; capsid shows improved muscle tropism vs AAV9.
- Long-term data from IGNITE DMD trial of SGT-001 expected in early 2023.

## SEC filing metadata
- accession: 0001193125-22-218018
- form_type: 8-K
- ticker: SLDB
- cik: 0001707502
- company_name: Solid Biosciences Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1707502/000119312522218018/0001193125-22-218018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1707502/000119312522218018/d385975d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-218018
- JSON: https://secwatch.observer/filing/0001193125-22-218018.json
- Plain text: https://secwatch.observer/filing/0001193125-22-218018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.